重组人促红素与左卡尼汀联合应用对血液透析肾性贫血患者的血生化指标影响及安全性分析

Effect and Safety of Recombinant Human Erythropoietin combined with Levocarnitine on blood Biochemical Indexes in Hemodialysis Patients with Renal Anemia

目的探究重组人促红素(recombinant human erythropoietin,rhEPO)与左卡尼汀联合治疗对血液透析肾性贫血患者的血生化指标影响及安全性。方法随机选取2022年1月—2023年12月在莆田学院附属医院接受血液透析的150例肾性贫血患者为研究对象,根据不同治疗方法分为两组,各75例。对照组单用rhEPO进行治疗,观察组使用rhEPO与左卡尼汀联合治疗,比较两组用药疗效、血生化指标、肾功能以及用药安全。结果治疗后,观察组临床用药总有效率为96.00%(72/75),高于对照组的85.33%(64/75),差异有统计学意义(χ^(2)=5.042,P<0.05)。观察组的3项血生化指标(平均红细胞血红蛋白浓度、血清铁蛋白以及平均红细胞血红蛋白含量)检测值均高于对照组,而2项肾功能指标(血肌酐与β2微球蛋白)检测值均低于对照组,差异有统计学意义(P均<0.05)。两组用药不良反应总发生率比较,差异无统计学意义(P>0.05)。结论rhEPO与左卡尼汀联合治疗能够提升血液透析肾性贫血患者的用药疗效,改善血生化指标及肾功能,不良反应发生于常规用药一致。

Objective To explore the effect and safety of combined treatment with recombinant human erythropoietin(rhEPO)and levocarnitine on blood biochemical indexes in patients with renal anemia undergoing hemodialysis.Methods A total of 150 patients with renal anemia undergoing hemodialysis in the Affiliated Hospital of Putian University from January 2022 to December 2023 were randomly selected as the research objects and divided into two groups according to different treatment methods,with 75 cases in each group.The control group was treated with rhEPO alone,and the observation group was treated with rhEPO combined with levocarnitine.The drug efficacy,blood biochemical indexes,renal function and drug safety were compared between the two groups.Results After treatment,the total effective rate of clinical medication in the observation group was 96.00%(72/75),which was higher than 85.33%(64/75)in the control group,and the difference was statistically significant(χ^(2)=5.042,P<0.05).At the same time,the detection values of three blood biochemical indexes(mean corpuscular hemoglobin concentration,serum ferritin and mean corpuscular hemoglobin content)in the observation group were higher than those in the control group,while the detection values of two renal function indexes(serum creatinine andβ2 microglobulin)were lower than those in the control group,and the differences were statistically significant(all P<0.05).The total proportion of adverse drug reactions between the two groups was close,and the difference was not statistically significant(P>0.05).Conclusion Combined treatment with rhEPO and levocarnitine can improve the drug efficacy of patients with renal anemia undergoing hemodialysis,improve blood biochemical indexes and renal function,and the occurrence of adverse reactions is consistent with that of conventional medication.